Aim: To further explore the impact of concomitant antiepileptic drugs (AEDs) on the efficacy and tolerability of adjunctive perampanel for focal epilepsy. Methods: Data were pooled from three phase III trials of adjunctive perampanel in patients (≥12 years of age) with refractory partial-onset seizures. Concomitant AEDs were categorized according to whether or not they were enzyme-inducing AEDs (EIAEDs; known to reduce perampanel plasma concentrations) or sodium channel blockers (SCBs). Post hoc analyses assessed the impact of co-administration of non-EIAED SCBs and the overall number of concomitant AEDs on changes in seizure frequency, 50% responder rates, rates of treatment-emergent adverse events (TEAEs), and rates of discontinuation due to TEAEs, in patients randomized to receive daily placebo or perampanel 2, 4, 8, or 12 mg. Results: Amongst 1480 randomized and treated patients, most were receiving two or more concomitant AEDs (n = 1273, 86.0%), one or more EIAEDs (n = 1083, 73.2%), and/or one or more SCBs (n = 1203, 81.3%) at Baseline. The magnitude of seizure reduction appeared unaffected by the presence of non-EIAED SCBs, but lower in the presence of multiple AEDs. Frequency of TEAEs did not appear to be affected by the presence of non-EIAED SCBs or multiple AEDs. Conclusion: Beyond the known interactions between perampanel and EIAEDs, perampanel efficacy appears to be unaffected by the use of concomitant non-EIAED SCBs, but may be reduced in the presence of multiple concomitant AEDs (possibly indicative of the presence of more refractory epilepsy). Nonetheless, with careful titration to balance efficacy and tolerability, perampanel may be combined with a range of AEDs, facilitating integration into treatment plans.
Introduction
Current antiepileptic drugs (AEDs) fail to confer seizure freedom in up to one-third of patients with epilepsy (Brodie et al., 2012) , warranting the development of new agents. New AEDs are initially evaluated as adjunctive treatments that are added to existing regimens of AEDs, which may vary in number and pharmacologic characteristics. When introducing a new AED, it is important to consider the potential for interactions with the AEDs that a patient is already taking, as they may affect treatment response.
In particular, pharmacokinetic interactions between AEDs often result from inducing or inhibitory effects on hepatic cytochrome P450 (CYP) enzymes, which are responsible for the metabolism of several, particularly older-generation, AEDs (Patsalos and Perucca, 2003) . The evidence for pharmacodynamic interactions between AEDs, as a result of their different mechanisms of action, is more limited, but of no less importance. Animal studies have indicated that combining AEDs with different mechanisms of action may confer synergistic effects, particularly for combinations including ␣-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor antagonists (Jonker et al., 2007) . In humans, evidence from observational studies has suggested synergistic efficacy when the sodium channel blocker (SCB) lamotrigine is combined with valproic acid (Brodie and Yuen, 1997; Pisani et al., 1999) , and a retrospective review of a US healthcare claims database has suggested that combining AEDs with different mechanisms of action may offer improved effectiveness compared with combinations with the same mechanisms, as measured by prolonged treatment continuation and reduced risks for hospitalization and emergency department visits (Margolis et al., 2014) . Other recent efforts to identify potentially beneficial AED combinations have utilized post hoc analyses of data from pivotal trials (Sake et al., 2010) .
Perampanel is a noncompetitive AMPA receptor antagonist, approved globally as an adjunctive treatment for partial-onset seizures, with or without secondary generalization, in patients aged 12 years and older (European Medicines Agency, 2012; Food and Drug Administration, 2012) . Approval was based on three placebo-controlled phase III pivotal studies in a total of 1480 patients with refractory partial-onset seizures who were receiving 1-3 concomitant AEDs (French et al., , 2013 Krauss et al., 2012) . As expected from the metabolism of perampanel by CYP3A4 (European Medicines Agency, 2012), pooled data from these studies indicated that enzyme-inducing AEDs (EIAEDs) reduced perampanel plasma concentrations without affecting the relationship between plasma concentration and reduction in seizure frequency (Gidal et al., 2013) . This was consistent with the pharmacokinetic effects of hepatic enzyme induction/inhibition previously reported in the literature (Johannessen Landmark et al., 2012; Patsalos, 2013) .
Subsequently, separate pooled analyses explored efficacy and safety outcomes when perampanel was co-administered with EIAEDs, confined to those demonstrated to confer clinically important induction of perampanel metabolism: carbamazepine, oxcarbazepine, and phenytoin (Gidal et al., 2015) . These analyses, based on actual (last) dose of perampanel, indicated that the efficacy of perampanel was reduced in the presence of these EIAEDs. Consistent with this, other pooled analyses, based on randomized perampanel dose, also showed a reduction of perampanel efficacy in the presence of carbamazepine, although the non-EIAEDs lamotrigine, levetiracetam, and valproic acid had no clear impact .
Overall, some clinically important inducers of perampanel metabolism (carbamazepine, oxcarbazepine, and phenytoin) have been characterized in terms of their impact on perampanel efficacy. However, beyond this, data appear lacking on the impact of other aspects of concomitant AED use, including other mechanisms of action. To help physicians integrate perampanel into treatment plans, we report post hoc analyses of the pooled phase III data by randomized dose, to further evaluate potential interactions between perampanel and concomitant AEDs. For the first time, the impact of concomitant administration of SCBs, and the impact of the number of concomitant AEDs is evaluated, with consideration of any potentially confounding effects of EIAEDs, including those not previously demonstrated to confer clinically important induction of perampanel metabolism. These analyses are intended to provide new insight into the importance of considering the different mechanisms of action and number of concomitant AEDs when initiating treatment with perampanel.
Methods

Overall phase III program
The double-blind, randomized, parallel-group studies 304 (ClinicalTrials.gov identifier: NCT00699972), 305 (NCT00699582), and 306 (NCT00700310) were conducted between April 2008 and January 2011, with patients enrolled from >40 countries across five continents. The designs and outcomes of these studies have been previously reported in full (French et al., , 2013 Krauss et al., 2012) . In brief, eligible patients were aged ≥12 years and were experiencing partial-onset seizures despite treatment with 1-3 AEDs. Patients could only be receiving one of the following AEDs: carbamazepine, phenytoin, phenobarbital, or primidonethese AEDs were considered EIAEDs at the outset of the studies, although, in subsequent analysis of perampanel plasma concentrations and pharmacokinetic modeling of the pooled phase III data, clinically important induction of perampanel metabolism was only demonstrable for carbamazepine, oxcarbazepine, and phenytoin (based on presence vs absence of each concomitant treatment) (Gidal et al., 2015) .
Following a 6-week Baseline Period, patients were randomized to once-daily double-blind treatment with placebo or perampanel (8 mg or 12 mg in studies 304 and 305; 2 mg, 4 mg, or 8 mg in study 306). In each Double-Blind Phase, perampanel was uptitrated to the randomized dose in weekly increments of 2 mg over a 6-week Titration Period. Patients then continued to receive the randomized dose for a 13-week Maintenance Period. Dose reduction due to intolerability was permitted.
The number of seizures per day was recorded in a daily patient diary. Any adverse events (AEs) that were new or worsened during the Double-Blind Phase were recorded as treatment-emergent AEs (TEAEs), and were classified according to the Medical Dictionary for Regulatory Activities (version 13.0 for studies 304 and 306, and version 13.5 for study 305).
Post hoc analyses of the impact of concomitant AEDs
The objective of the present analyses was to further evaluate potential interactions between perampanel and other AEDs based on mechanism of action and number of concomitant AEDs.
Since the efficacy of perampanel is already known to be reduced in the presence of EIAEDs that induce perampanel metabolism, these analyses explored effects both in the presence and absence of EIAEDs. EIAEDs were defined here as carbamazepine, oxcarbazepine, phenytoin, eslicarbazepine, phenobarbital, primidone, or topiramate. This definition encompassed the AEDs previously demonstrated to cause clinically important induction of perampanel metabolism (group 1 EIAEDs: carbamazepine, oxcarbazepine, and phenytoin), but also other AEDs typically recognized as EIAEDs that had not demonstrated such a clear inducing effect in previous analyses of perampanel data, possibly due to small patient numbers in some cases (group 2 EIAEDs: eslicarbazepine, phenobarbital, primidone, and topiramate).
As sodium channel blockade is one of the most common mechanisms of action of AEDs, the impact of the co-administration of SCBs on perampanel efficacy and safety was evaluated. SCBs were defined here as carbamazepine, eslicarbazepine, oxcarbazepine, phenytoin, lacosamide, lamotrigine, or rufinamide. To help delineate the effects of EIAEDs and SCBs, these analyses focused on the three SCBs that were not also EIAEDs (lacosamide, lamotrigine, and rufinamide). Patients were therefore categorized according to whether or not they had received any EIAEDs, and whether or not they had received any non-EIAED SCBs.
To evaluate the impact of the number of concomitant AEDs on perampanel efficacy and safety, patients were categorized according to whether they had received one, two, or three concomitant AEDs, and whether those concomitant AEDs included no EIAEDs or one EIAED (patients receiving more than one EIAED were excluded from this analysis to avoid confounding effects).
Analyses were performed to assess the impact of mechanism of action and number of concomitant AEDs on median percentage change in overall seizure frequency per 28 days (Baseline vs Double-Blind Phase) and 50% responder rate (patients with >50% reduction from Baseline in seizure frequency per 28 days in the Maintenance Period) in patients randomized to receive placebo or perampanel. Efficacy analyses were based on the pooled intent-totreat analysis set, consisting of all randomized and treated patients with any post-Baseline seizure data, with last observation carried forward. All efficacy analyses were based on randomized perampanel dose. Median percentage change in overall seizure frequency per 28 days was compared between groups, based on a rank analysis of covariance with Baseline AED category as a factor, prerandomization seizure frequency as a covariate, and 50% responder rate was compared between groups using Fisher's exact test.
Analyses were also performed to assess the impact of these concomitant AEDs on the frequencies of the 10 most common TEAEs reported across the phase III studies , and discontinuations due to TEAEs, based on the safety analysis set (all randomized and treated patients). TEAE incidence was compared between groups using Fisher's exact test.
Standard protocol approvals, registrations, and patient consents
All studies were performed in accordance with the Declaration of Helsinki, Good Clinical Practice ICH-E6 Guideline CPMP/ICH/135/95, European Clinical Trial Directive 2001/20/EC, and the US Code of Federal Regulations Part 21. Trial protocols, amendments, and informed consent were reviewed by national regulatory authorities in each country and independent ethics committees or institutional review boards for each site. All patients gave written, informed consent before participation.
Results
Patients
A total of 1480 patients were randomized and treated in the three phase III pivotal studies. Demographics for this pooled safety analysis set have been reported previously . The use of concomitant AEDs at Baseline is shown in Table 1 . Most patients were receiving two or more concomitant AEDs at Baseline (one, n = 206, 13.9%; two, n = 751, 50.7%; three, n = 522, 35.3%; data missing for one patient), and the majority were receiving one or more EIAEDs (n = 1083, 73.2%) and/or one or more SCBs (n = 1203, 81.3%). Of the patients receiving EIAEDs (n = 1083), most received carbamazepine, oxcarbazepine and/or phenytoin (n = 866, 80.0%), which are known to be associated with clinically important induction of perampanel metabolism, but few received two or more of these three agents (n = 16, 1.5%). The most commonly administered concomitant EIAEDs were the SCBs carbamazepine (n = 491, 33.2%) and oxcarbazepine (n = 270, 18.2%), while the most commonly administered concomitant non-EIAEDs were the SCB lamotrigine (n = 458, 30.9%) and the non-SCBs valproic acid (n = 478, 32.3%) and levetiracetam (n = 435, 29.4%). There were 1478 patients included in the pooled intent-to-treat analysis set.
Impact of concomitant AEDs on perampanel efficacy
When patients were categorized according to whether or not they had received any EIAEDs, and whether or not they had received any non-EIAED SCBs, Baseline patient demographics (gender, age, BMI) remained largely balanced between groups (Table 2 ) However, there was some variation in terms of epilepsy characteristics. Most notably, there was broad inter-patient variation in Baseline seizure frequency: while median values appeared balanced between groups (10.9-13.1), individual values ranged from 1.4 to 4504 seizures per 28 days. Similarly, mean time since epilepsy diagnosis was largely balanced between groups (217.0-258.8 months), but large standard deviations indicated broad inter-patient variability (range was 6.0-819.0 months). In addition, the number of concomitant AEDs at Baseline varied between groups; for example, the use of just one concomitant AED at Baseline was most frequent in patients who were not receiving any EIAEDs, while the use of three concomitant AEDs at Baseline was most frequent in patients who were receiving one or more EIAEDs.
In accordance with previously reported analyses, median reductions in seizure frequency and 50% responder rates were generally greater in patients randomized to receive perampanel 4-12 mg than in those randomized to placebo (Fig. 1) . Perampanel exposure was reduced in the presence of EIAEDs (Table 3) and there were corresponding reductions in efficacy in this setting (Fig. 1 ).
Efficacy outcomes with perampanel 12 mg appeared to be reduced to a similar extent in patients receiving group 1 EIAEDs (those previously demonstrated to cause clinically important induction of perampanel metabolism: carbamazepine, oxcarbazepine, and phenytoin) as in those receiving group 2 EIAEDs (those that had not previously demonstrated such clear induction of perampanel metabolism: eslicarbazepine, phenobarbital, primidone, and topiramate; Table 4 ). However, in patients treated with perampanel 8 mg, the impact of group 2 EIAEDs was weaker than that of the group 1 EIAEDs, while in patients treated with perampanel 4 mg, the group 2 EIAEDs were not associated with any reductions in efficacy. Alongside these observations, it should be noted that perampanel exposure was shown to be reduced in the presence of group 2 EIAEDs, but the effect was weaker than that of the group 1 EIAEDs (Table 3) .
The presence or absence of non-EIAED SCBs had no clear, consistent impact on efficacy outcomes with perampanel, regardless of whether patients were also receiving concomitant EIAEDs (Fig. 1). 
Impact of the number of concomitant AEDs on perampanel efficacy
In patients who were not receiving any concomitant EIAEDs, the efficacy of pooled doses of perampanel 2-12 mg declined as the number of concomitant AEDs increased from one to three (Fig. 2) . In patients who were receiving one concomitant EIAED, there was a similar but less marked trend.
Impact of concomitant AEDs on perampanel tolerability
Overall, in patients randomized to receive perampanel 2-12 mg, there were significantly lower rates of TEAEs leading to discontinuation in patients who were receiving concomitant EIAEDs than in those who were not (7.1% vs 16.1%, respectively, p < 0.001; Table 5 ). However, the frequencies of individual TEAEs appeared largely similar regardless of whether EIAEDs or non-EIAED SCBs were coadministered (Table 5 ). The exceptions were the following three TEAEs, which were significantly less common in patients receiving one or more EIAEDs compared with those receiving no EIAEDs: fatigue (7.3% vs 11.8%, respectively, p < 0.05), nausea (4.0% vs 8.6%, p < 0.01), and ataxia (2.5% vs 6.1%, p < 0.05).
There were no clear trends in the frequencies of TEAEs with regard to the number of concomitant AEDs received, either in the presence or absence of one EIAED (Table 6) . 
Discussion
Overall, the present analyses indicate that the efficacy and tolerability profiles of perampanel remain largely consistent with the previously reported overall pooled phase III data , with therapeutic benefit observed irrespective of the presence or absence of various categories of concomitant AEDs. Compared with placebo, there were generally improvements in seizure frequency and responder rates at perampanel doses of 4-12 mg, and dizziness, somnolence, and headache were amongst the most frequently reported TEAEs when all perampanel doses were pooled. Also consistent with previously reported analyses, perampanel exposure was reduced in the presence of EIAEDs, with corresponding reductions in efficacy. Group 2 EIAEDs, which had not demonstrated clinically important induction of perampanel metabolism, were shown to reduce perampanel exposure, although to a lesser extent than the established group 1 EIAEDs. Group 1 and group 2 EIAEDs were associated with similar reductions in efficacy when co-administered with perampanel 12 mg, but the impact of the group 2 EIAEDs was less pronounced in patients receiving lower perampanel doses, perhaps due to the observed weaker effect on perampanel exposure. Nonetheless, the analyses provide overall evidence Table 3 Steady-state perampanel plasma concentrations (CavSS) according to perampanel dose and the presence of concomitant EIAEDs, including group 1 EIAEDs (carbamazepine, oxcarbazepine, and phenytoin), and group 2 EIAEDs (phenobarbital, primidone, and topiramate; no patients were receiving the group 2 EIAED eslicarbazepine). EIAED (enzyme-inducing antiepileptic drug), SD (standard deviation).
Table 4
Median percentage changes in seizure frequency per 28 days (Baseline vs Double-blind Treatment Period) and 50% responder rates (Baseline vs Maintenance Period) in patients receiving placebo or perampanel 2-12 mg in combination with 1-3 concomitant AEDs, including: one or more group 1 EIAEDs (carbamazepine, oxcarbazepine, and phenytoin), one or more group 2 EIAEDs (eslicarbazepine, phenobarbital, primidone, and topiramate), or no EIAEDs.
Placebo (n = 441) Perampanel 2 mg (n = 180) 4 mg (n = 172) 8 mg (n = 431) 12 mg (n = 254) of weak enzyme-inducing properties for the group 2 EIAEDs, supporting the approach to EIAED classification in the present study.
Although the frequencies of TEAEs were largely similar, rates of discontinuation due to TEAEs were lower in patients who received concomitant EIAEDs than in those who did not, implying that the TEAEs were less severe. Overall, the analyses by EIAED use suggest that initial titration to a higher dose of perampanel may be anticipated when it is introduced to a regimen containing an EIAED, and higher doses of perampanel may be required to gain optimal seizure control. However, ultimately perampanel should always be titrated to an effective and tolerated dose in all patients, based on treatment response, regardless of concomitant AEDs (European Medicines Agency, 2012) . Prospective studies are needed to more clearly define perampanel dosing strategies when EIAEDs are co-administered. In contrast, concomitant administration of non-EIAED SCBs had no consistent impact on the efficacy and tolerability of perampanel, suggesting that clinically significant pharmacodynamic interactions between perampanel and SCBs are unlikely. Among patients who did not receive any EIAEDs, the apparent low rates of neurotoxic TEAEs in those who received one or more SCBs were intriguing and may warrant further investigation. However, as this comprised the smallest patient group, a chance finding cannot be excluded.
In terms of the number of AEDs received, perampanel efficacy appeared to diminish as the number of concomitant AEDs increased. This may have reflected the likelihood that patients receiving more AEDs may have had more drug-resistant epilepsy. While this effect was apparent in patients who were not treated with any EIAEDs, it should be considered that, in clinical practice, patients receiving multiple concomitant AEDs may also be more likely to be receiving one or more EIAEDs, which could further reduce perampanel efficacy, in accordance with other observations reported here. However, in any case, the data reported here indicate that a proportion of patients receiving three concomitant AEDs may still be able to derive benefit from adjunctive perampanel. Reassuringly, patients who received more concomitant AEDs did not experience more TEAEs.
There are inherent limitations when attempting to evaluate the impact of concomitant AEDs in a post hoc analysis. These limitations primarily arise because most patients are treated with more than one concomitant AED and it is, therefore, difficult to resolve the contribution of each individual drug. In addition, there are challenges in defining the precise mechanism of action of some broad-spectrum AEDs, which may exhibit sodium channel blocking activity, yet the degree to which this contributes Table 6 Impact of the number of concomitant AEDs on TEAE frequencies in patients treated with perampanel (pooled doses, 2-12 mg). 10 (6.5) 4 (7.3) 1 (1.3) 13 (3.9) 10 (4.5) Nasopharyngitis 5 (7.1) 9 (5.8) 3 (5.5) 4 (5.3) 13 (3.9) 9 (4.0) Upper respiratory tract infection 1 (1.4) 3 (1.9) 3 (5.5) 2 (2.6) 15 (4.5) 12 (5.4) Ataxia 2 (2.9) 11 (7.1) 4 (7.3) 0 (0.0) 12 (3.6) 5 (2.2) Balance disorder 4 (5.7) 6 (3.9) 0 (0.0) 3 (3.9) 9 (2.7) 5 (2.2) AED (antiepileptic drug), EIAED (enzyme-inducing antiepileptic drug), TEAE (treatment-emergent adverse event).
to their pharmacologic effects is debatable (e.g., valproic acid, zonisamide). In addition, as a conservative approach, we included well-recognized enzyme inducers for which clinically relevant effects on perampanel metabolism have not been established. The complexity of grouping AEDs also limits the investigation of other mechanisms of interest, such as inhibition of glutamatergic neurotransmission, which are most pertinent to perampanel as an AMPA receptor antagonist. Finally, it is important to note the broad inter-patient variability in terms of the severity of the epilepsy and the responsiveness to different treatments.
In conclusion, beyond the known interactions between perampanel and EIAEDs, the present analyses suggest that adjunctive perampanel may improve efficacy outcomes in patients with refractory partial-onset seizures with a consistent tolerability profile, regardless of the use of concomitant non-EIAED SCBs or the overall number of concomitant AEDs. However, the magnitude of efficacy may be reduced in the presence of multiple AEDs. These findings should be considered when introducing and titrating perampanel to achieve optimal treatment outcomes.
